Related Experiment Videos
Tubulin-polymerization inhibitors derived from thalidomide
Shunsuke Inatsuki1, Tomomi Noguchi, Hiroyuki Miyachi
1Institute of Molecular and Cellular Biosciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-0032, Japan.
Bioorganic & Medicinal Chemistry Letters
|December 18, 2004
Summary
A novel compound, 2-(2,6-Diisopropylphenyl)-5-hydroxy-1H-isoindole-1,3-dione (5HPP-33), demonstrates potent tubulin polymerization inhibition. This activity is comparable to established inhibitors like colchicine, suggesting therapeutic potential.
Area of Science:
- Medicinal Chemistry
- Molecular Biology
- Pharmacology
Background:
- Thalidomide analogs are investigated for therapeutic potential.
- Tubulin polymerization is a key target for cancer therapies.
- Understanding structure-activity relationships is crucial for drug development.
Purpose of the Study:
- To evaluate the tubulin polymerization inhibitory activity of 2-(2,6-Diisopropylphenyl)-5-hydroxy-1H-isoindole-1,3-dione (5HPP-33).
- To compare the activity of 5HPP-33 with known tubulin polymerization inhibitors.
- To assess the activity of thalidomide metabolites.
Main Methods:
- Synthesis and structural characterization of 5HPP-33.
- In vitro tubulin polymerization assays.
- Comparison with rhizoxin and colchicine.
Main Results:
- 5HPP-33 exhibited potent tubulin polymerization inhibitory activity.
- The inhibitory potency of 5HPP-33 was comparable to rhizoxin and colchicine.
- 5-hydroxythalidomide, a metabolite, showed moderate inhibitory activity.
Conclusions:
- 5HPP-33 is a potent inhibitor of tubulin polymerization.
- The hydroxyl group at the 5-position is significant for inhibitory activity.
- 5HPP-33 represents a promising lead compound for further drug development.